Significant benefit of Nivolumab treating PD-L1 positive metastatic pulmonary carcinosarcoma: a case report and literature review

Immunotherapy has recently become a new focus for the treatment of malignant tumors following the surgery, chemotherapy, radiotherapy, and molecular targeted therapy. Nivolumab, a human monoclonal antibody, is the first programmed cell death protein-1 (PD-1) inhibitor, which can prohibit the interac...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhe, Chen, Yishan, Ma, Mingxia, Hao, Junli, Ding, Rui, Han, Lixin, Zou, Jiayun, Zhang, Lina, Meng, Qin, Qu, Xiujuan, Liu, Yunpeng, Zhao, Mingfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707114/
https://www.ncbi.nlm.nih.gov/pubmed/29221220
http://dx.doi.org/10.18632/oncotarget.19089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707114/
https://www.ncbi.nlm.nih.gov/pubmed/29221220
http://dx.doi.org/10.18632/oncotarget.19089

Ejemplares similares